GeneticTechnologies BREVAGen Brustkrebsrisiko Test

GeneticTechnologies sichert sich US-Zulassung für Start von BREVAGen Brustkrebsrisiko Test.Kaufen?

13/04/2012 ImmunAid Pty. Ltd. secures cornerstone funding
www.asx.com.au/asxpdf/20120413/pdf/425lf56n9myrwb.pdf

hat sich ja wieder einiges getan, vor allem BrevaGen hat deutlich angezogen am Markt..
aber der Reihe nach..

19/04/2012   Forfeiture of options
www.asx.com.au/asxpdf/20120419/pdf/425ps4353n1rmn.pdf

20/04/2012   Appendix 3B
www.asx.com.au/asxpdf/20120420/pdf/425qjhzl81px5h.pdf

24/04/2012 Appendix 4C - quarterly
www.asx.com.au/asxpdf/20120424/pdf/425swy9ryk8d73.pdf

BreavGen News die zum Kursanstieg beitrug ist die vom 22.05.!

09/05/2012 Settlement with GeneSeek
www.asx.com.au/asxpdf/20120509/pdf/42653xdm9syf2q.pdf

22/05/2012 BREVAGen credentialing update
www.asx.com.au/asxpdf/20120522/pdf/426dgtmp0hrb00.pdf

30/05/2012   Appendix 3B
www.asx.com.au/asxpdf/20120530/pdf/426kd561m3dlt9.pdf

READY TO GOOO

09/07/2012 Non-coding licensing update
www.asx.com.au/asxpdf/20120709/pdf/4279vp256ygszg.pdf

Das  Seminar über BREVAGen und Brustkrebs Risikobewertung findet am Freitag,  17 August, 2012 von 12.30 Uhr bis 02.00 Uhr in The Woodlands Institut  für Gesundheit und Wellness in 26110 Oak Ridge Drive, The Woodlands,  Texas. Alle Interessierten, die mehr über Brustgesundheit und BREVAGen ist herzlich eingeladen.

 

                                       

THE WOODLANDS, Texas--(BUSINESS WIRE)--Dr. Mila McManus of The        Woodlands Institute for Health and Wellness, one of the first        physicians in the nation to make the BREVAGen™        predictive risk test available to her patients, is conducting a free        community seminar on August 17, 2012 to introduce BREVAGen and discuss        its importance in breast cancer risk assessment. Clinically validated,        BREVAGen is the latest advance in assessing a woman’s unique risk of        developing non-familial or sporadic breast cancer, which accounts for 70        to 80 percent of all breast cancer cases.

...wie man sieht,der Test startet erst jetzt so richtig,immerr noch Zeit in Genetic Techn. zu investieren!

so long!

TM

 

 

 

Genetic Technologies Announces BREVAGen(TM) Cleared for Sale in California

 

24/07/2012   Director Appointment/Resignation
www.asx.com.au/asxpdf/20120724/pdf/427kc5pcr21w2p.pdf



und wie vom Ticketman schon erwähnt..

26/07/2012 BREVAGen cleared for sale in California
www.asx.com.au/asxpdf/20120726/pdf/427lrvt2fwbyht.pdf

30/07/2012 Appendix 4C - quarterly
www.asx.com.au/asxpdf/20120730/pdf/427ntxtb0cfw74.pdf

August 8, 2012
Genetic Technologies Receives CE Mark Approval for BREVAGen™
Melbourne, Australia; August 8, 2012: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE)
announced today that it has received European CE Mark approval for BREVAGen™, the Company’s
breast cancer risk test. The CE Mark designation will allow BREVAGen™ to be sold in the EU and
other countries that recognise the CE Mark. The initial commercial focus will be in the key markets of
France and Germany.
Breast cancer is the most common form of cancer in European women. In 2008, annual breast cancer
incidence in the European Union (EU-27) was over 330,000. This is nearly double the incidence rate in
the U.S. of just over 180,000 cases per year (cited electronically at globocan.iarc.fr/). Approximately 80%
of women who develop breast cancer develop non-familial or sporadic breast cancer, that is, they have
little or no family history of the disease.
“The achievement of CE Mark for our flagship BREVAGen™ product is a major milestone for the
Company,” stated Dr. Paul MacLeman, CEO of Genetic Technologies. “Given the significant incidence
rate of breast cancer in the EU, there is a critical need for enhanced risk assessment tools, leading to
improved preventative management and surveillance.”
BREVAGen™ uses a novel approach to non-familial breast cancer risk assessment, combining validated
breast cancer susceptibility genetic markers with a patient’s individual clinical risk factors to yield an
integrated, more accurate risk score. The test was launched in June 2011 in select regions in the U.S.
and is currently available in 48 U.S. States.
CE Marking
Conformité Européenne, meaning European conformity, is a mandatory conformity mark for certain
products placed on market in the European Economic Area including medical devices and IVD tests.
CE Marking ensures that the manufacturer’s product conforms to the essential requirements of the
relevant European health, safety and environmental protection legislation. IVD tests, in accordance with
the EU directive 98/79/EC for IVDD, must be safe and function as per the manufacturer’s intended
purpose. BREVAGen’s™ CE Marking certification was conducted by MT Promedt Consulting GmbH,
a globally recognised European Authorized Representative with offices in Germany and the U.S.
ENDS
 
FOR FURTHER INFORMATION PLEASE CONTACT
Dr. Paul D.R. MacLeman     Rudi Michelson (Australia)   Laura Landry (USA)
Chief Executive Officer     Monsoon Communications   BluePrint Life Science Group
Genetic Technologies Limited   +61 3 9620 3333     +1 (415) 375.3340  Ext. 2022
Phone: +61 3 8412 7000

 

www.pazzosognofinanza.com/...fici&op=dettaglio&id=6409

MELBOURNE, AUSTRALIA–(Marketwire – Jul 26, 2012) – Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that the Laboratory Field Services Unit of the California Department of Public Health (CDPH) has granted a license to the Companys Australian-based laboratory. BREVAGen™ may now be offered for sale into the State of California.

Based solely on incidence rates, California represents approximately 11% of the United States total breast cancer incidents, with over 25,000 new cases of breast cancer diagnosed annually. (ACS Breast Cancer Facts & Figures 2011-12, ACS Cancer Facts & Figures 2012)

We expect California to be a large and significant market for BREVAGen™, said Dr. Paul MacLeman, Genetic Technologies Chief Executive Officer. We will be applying sales and marketing resources to drive test adoption and sales in the State in the coming weeks.

Another stock that’s quickly moving within range of triggering a near-term breakout trade is Genetic Technologies (GENE), which provides genetic testing services.  This stock is off to a strong start in 2013, with shares up sharply by 24%.

If you look at the chart for Genetic Technologies, you’ll notice that  this stock has been uptrending strong for the last two months, with  shares moving higher from its low of $2.10 to its recent high of $2.90 a  share. During that uptrend, shares of GENE have been consistently  making higher lows and higher highs, which is bullish technical price  action. That move has quickly pushed shares of GENE within range of  triggering a near-term breakout trade.

Market players should now look for long-biased trades in GENE if it  manages to break out above some near-term overhead resistance levels at  $2.75 to $2.80 a share and then once it takes out more resistance at  $2.90 to its 200-day at $3.14 a share with high volume. Look for a  sustained move or close above those levels with volume that hits near or  above its three-month average action of 38,979 shares. If that breakout  triggers soon, then GENE will set up to re-test or possibly take its  next major overhead resistance levels at $3.40 to $3.80 a share. Any  high-volume move above those levels will then put $3.95 to $4.22 into  range for shares of GENE.

Traders can look to buy GENE off any weakness to anticipate that  breakout and simply use a stop that sits right below its 50-day at $2.47  a share or around more support at $2.36 a share. One can also buy GENE  off strength once it clears those breakout levels with volume and then  simply use a stop that sits right below its 50-day at $2.47 a share. I  would add to either position once GENE clears its 200-day at $3.14 a  share with heavy upside volume.

01:33 GENETIC TECHNOLOGIES LIMITED: GTG receives certification for New York State

Mit einer Marktkapitalisierung von nur 17 Millionen US-Dollar hat GENE nicht  viel Aufmerksamkeit, und ist schon gar nicht in der Lage, die Art von Publikum, dass Quest Diagnostics oder sogar Hologic auf sich zieht. Da sie aber sagen, gute Dinge kommen in kleinen Paketen, Genetic Technologies ist wohl eine gute Sache. Wie so? Es ist der Hersteller eines Brustkrebs-Risiko-Assessment-Test genannt BREVAgen. Zwar gibt es thematisch ähnliche Diagnose-Tools da draußen, es gibt aber nichts anderes auf dem Markt ganz wie BREVAgen. Es ist nicht das einzige Diagnose / Risiko-Assessment-Tool das Unternehmen macht, aber es ist das Hauptprodukt des Unternehmens...mit Nettogewinnen am Horizont.
Sie sind am fernen Horizont, wohlgemerkt, aber es gibt Grund zur Hoffnung.
Genetic Technologies hat kürzlich angekündigt, dass sechs weitere Brustkrebsdiagnostik in Behandlungszentren w.gestartet, mit den BREVAgen Diagnose-Tool. Jedes Mal, dass Tally steigt, ist schrittweise höhere Umsätze auf dem Weg.
Während all das ist die Grundlage für Optimismus, das Potential des Tests ist nicht der Hauptgrund, als Investor möchten Sie vielleicht GENE über eine Beteiligung an einem Konkurrenten Unternehmen wie Hologic oder Quest Diagnostics wählen...  Grund genug Genetic Technologies zu kaufen ist im Moment, dass es technisch aus einem Abwärtstrend aufsteigt und den Startschuss für einen Aufwärtstrend anzeigt.
Mal gucken. GENE steigt über die 100-Tage-Linie,jeder Schritt über die 200-Tage-Linie ist ein Katalysator. Unabhängig davon, welche Linien überschritten wurden oder nicht, wenn es sie überquert, ist der Paradigmenwechsel deutlich.
Es gibt nicht so etwas wie eine Garantie an der Wall Street. Aus Risiko-versus-Belohnung Sicht mit der Action in den letzten Tagen ist Genetic Technologies Limited eine hohe Belohnung mit nur einem bescheidenen Maß an Risiko. Es ist sicherlich eine überzeugendere Risiko- / Ertragssituation als Quest Diagnostics und Hologic sie zu diesem Zeitpunkt serviert...
www.smallcapnetwork.com/...a/1789/article/view/p/mid/3/id/602/

www.asx.com.au/asx/statistics/...isplay=pdf&idsId=01596930

beteiligt, sollte man sich ein paar Aktien sichern, in Australien schon bei 0,036 AUD
Geheimtipp...?
Die Firma will auch in den USA expandieren.
Die Aktie verlässt ihren Abwärtstrend und schießt nach oben...

in den usa 8$ und hier 0,05€? Sie tradet dort unter dem Symbol GENE.  

January 20, 2015 Securities & exchange Commission 450 Fifth Street, NW Washington, DC 20549 Attn.: Document Control

RE:American Depositary Receipts representing thirty deposited shares of Genetic Technologies Limited. The Prospectus has beenrevised to reflect the new ratio, which has been changed to read: “Each American Depositary Share representsone hundred fifty deposited Shares”. The Bank of New York Mellon - ADR Division

Genetic Technologies Ltd (GTG.AX)
ASX
0.0680 Up 0.0180(36.00%) 16 Feb 16:10

GENE
Genetic Technologies Ltd Stock Quote & Summary Data
$8.04  Exchange: NASDAQ
*  
1.90
30.94%
*Delayed - data as of Feb. 13, 2015
Read more: www.nasdaq.com/symbol/gene#ixzz3RuqVrEX4

GTG hat heute über 30% gemacht, bin gespannt wie es morgen aussieht entsprechend wird sich dann der Wert evtl anpassen. Einfach GENEial das Teil

www.marketwired.com/press-release/...plusr-asx-gtg-2011151.htm

Genetic Technologie Ltd; Deutsche Bank Buys.
Nov 23, 2015 4:09 AM | about stocks: GENE

If you haven't been following the news that's been circulating lately around Genetic Technologies Limited, then read along.

As of November 17th, 2015, DB filed a Form 603, and declared themselves a substantial holder with 579,200 ADRs. Let's clear up some of this noise, there is a lot of misleading information floating around social media.

ADR: American Depository Receipt, is one of the most convenient and popular ways to buy stocks of companies based overseas. This is exactly what DB did on November 17th. The 579,200 ADR's is equivalent to 86,880,000 ordinary shares under U.S. dollars. This also gives DB the voting power of 5.07%.

So why should investors care?

Genetic Technologies Limited (NASDAQ:GENE): With a less than impressive balance sheet, and the reputation for burning capital at an excessive rate, just got a substantial holder from DB? Why would DB be risking a stake in such a speculative company?

News: This transaction comes off the heals of a insider transaction of the CEO. Furthermore, earlier on November 2, 2015, Phenogen Sciences, Inc (U.S. subsidiary of Australia-based Genetic Technologies and maker of BrevaGenplus) commented on the American Cancer Society's (ACS) recent breast cancer screening guidelines, which plays directly in favor of BrevaGenplus. The company makes it clear they are ready to solve this clinical gray area, and offered some guidance on how their product can solve this new protocol from the ACS.

Speculative pharmaceuticals are typically known for their cash burning capabilities and their low ROI on investment returns. Although, once and awhile these sleeping giants can reward those shareholders who do their due diligence of their homework on these speculative investments. With that said, when a substantial player steps up to the plate, it's good to take notice and due some further research into what is really going on here.

What is BrevaGenplus and BrevaGen?

It's a simple swab-based test that help determines the risk of breast cancer. It's the first test of its kind validated to asses both 5-year and lifetime risk for sporadic breast cancer. With early detection assistance from BREVAGen, 95% of these women will have even a stronger chance of survival.

How is this product being accepted in the open market?

From FY2012 Q1 samples received were mere 78, in closing on FY14, samples received in Q4 were 1,096. Which suggest the marketing of the brand from the sales team has gathered some steam, and with BREVAGenplus just released October of 2014, this story is fresh and has plenty of room to gather some momentum.

All these catalyst and more could send this speculative pharma company to new heights. It's important to keep this company on your radar, since it's a low float stock and small catalyst can send this stock roaring back to early January highs.

Disclosure: I am/we are long GENE.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Themes: long-ideas, event-special-situations, new-shareholder-base, speculative, underfollowed Stocks: GENE  

Wir waren beim letzten Pump vor ein paar Wochen schon dabei.
Kommt jetzt der nächste?